Results 111 to 120 of about 181,836 (188)

Conversion Rate Of Ocular Myasthenia Gravis To Generalized Myasthenia Gravis

, 2013
Ocular myasthenia gravis (OMG) is a common presentation to the neuro-ophthalmology clinic. Previous studies have reported that generalized myasthenia gravis (GMG) develops in 50% or more of patients presenting with OMG, usually within 2 years.
Lina Nagia; Khawla Abusamra; Eric R. Eggenberger
core  

Treatment Outcome in Ocular Myasthenia Gravis

, 2020
Ocular Myasthenia Gravis (OMG) is an autoimmune disease that affects the neuro-muscular junction resulting in ptosis and/or diplopia without general or bulbar symptoms. OMG patients can suffer from disabling ocular symptoms. The outcome of treatment with
Melody Merati; Wayne Cornblath; Lina Nagia
core  

Quality of life in purely ocular myasthenia in Japan [PDF]

Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS).
Konno, Shingo, Murai, Hiroyuki, Imai, Tomihiro, Motomura, Masakatsu, Suzuki, Norihiro, Nagane, Yuriko, Oji, Satoru, Nakane, Shunya, Masuda, Masayuki, Utsugisawa, Kimiaki, Suzuki, Shigeaki, Tsuda, Emiko   +11 more
core  

Study on the clinical and electrophysiological characteristics of nerve function in myasthenia gravis patients in Vietnam

SAGE Open Medicine
Background: In Vietnam, there is limited research on the role of nerve conduction in myasthenia gravis and its association with clinical features. Objective: This study aims to describe the electrophysiological features in patients with myasthenia gravis.
Tho Kieu Anh Pham, Phuong Van Pham, Tung Dinh Le, Binh Thanh Nguyen, Trung Kien Nguyen, Tam Thai Thanh Tran, Sam Phan Hai Nguyen, Minh Van Le   +7 more
doaj   +1 more source

Comparison of diagnostic tests in myasthenia gravis

, 1983
Results of 3 tests, intravenous edrophonium chloride, EMG, and acetylcholine receptor antibody testing, were compared in patients with generalised and ocular myasthenia gravis.
Nicholson, G. A., Griffiths, Lyn R., McLeod, J. G.   +2 more
core  

Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis

Purpose: To synthesize the evidence and generate a combined weighted measure on the frequency of ocular manifestations of mucous membrane pemphigoid (OMMP).
Romero-Osorio M.J., Oliver-Hernández M.V., Romero-Santos S., Barragán A.M., Pardo-Pizza D., de-la-Torre A., Cifuentes-González C., Parra-Tanoux D., Bocanegra-Oyola N.   +8 more
core   +1 more source

Unilateral Proptosis Caused by Ocular Myasthenia Gravis

, 2011
Proptosis is a little-recognized finding in ocular myasthenia gravis, except when attributed to coexistent thyroid ophthalmopathy.
J. Alexander Fraser; Michael W. Nicolle; David A. Nicolle
core  

Ocular Myasthenia Gravis: AChR Seropositivy and Generalization

, 2020
Ocular Myasthenia Gravis (OMG) is an autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of extraocular muscles, levator palpebrae, and orbicularis oculi resulting in fatigable ptosis and binocular diplopia.
Mariana de Virgiliis; Luciana Iacono; Maria Laura Braccia Gancedo; Pablo Perez Vega; Luciana Lagos; Haydee Martinez; Lidia Sarotto; Marcela Dulce; Dolores Ribero Ayerza; Glenda Dibner; Mariana Ingolotti
core  

Prevalence of Thymoma in Ocular Myasthenia Gravis (.pdf)

, 2016
The prevalence of thymoma in ocular myasthenia gravis has not been explicitly investigated in the medical literature. Published data vary and chiefly consist of smaller case series. The purpose of this study is to determine the prevalence of thymoma in a
Anthony J. Brune; Lina Nagia; Joao Lemos; Lindsey B. De Lott; Khawla Abusamra; Wayne T. Cornblath; Eric R. Eggenberger
core  

Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study. [PDF]

Front Immunol
Sun C, Liu D, Tang Y, Zhang B, Guo R, Gao T, Cao X, Hao S, Wang Q, Yu H, Chang T.   +10 more
europepmc   +1 more source